FDA Application Custom Crystal

Custom crystal commemorating the submission of a New Drug Application (NDA) to the FDA. The application for Impel NeuroPharma’s migraine treatment INP104 was supported by a Phase 3, open-label safety and tolerability trial. (20ALJ356)